Key Takeaways
- • Novartis has agreed to acquire UK-based biotech firm Myricx for more than $2 billion, representing a major exit for early-stage cancer therapy development.
- • Brandon Capital, an Australian venture capital firm, will receive more than $300 million from the Myricx sale, delivering a significant windfall to its superannuation fund backers.
- • The deal underscores sustained institutional investor appetite for oncology-focused biotech assets despite historical volatility in the sector.
- • Australian superannuation funds gain material liquidity event from venture capital allocation, demonstrating returns on alternative asset exposure.
Summary
Swiss pharmaceutical giant Novartis has agreed to pay more than $2 billion to acquire Myricx, a UK-based biotech company focused on early-stage cancer therapeutics. The acquisition represents a substantial exit event for Brandon Capital, an Australian venture capital firm that founded and backed the company, with the VC firm positioned to receive more than $300 million from the transaction.
Brandon Capital's superannuation fund investors—primarily Australian pension funds—stand to benefit materially from the sale proceeds. The deal illustrates the outsized return potential embedded in venture capital allocations within superannuation portfolios, where a single successful biotech exit can deliver multiples on capital deployed across an entire fund vintage.
The Myricx acquisition reflects Novartis's strategic focus on expanding its oncology pipeline through acquisition of development-stage assets. For institutional investors and family offices with exposure to venture capital vehicles or direct biotech holdings, the transaction signals continued pharmaceutical industry appetite for innovative cancer therapies, particularly those in early development phases where acquisition multiples remain elevated relative to mature-stage programs.
The timing of this exit in mid-2026 aligns with a broader institutional reallocation toward life sciences and healthcare innovation, sectors that have demonstrated resilience and defensive characteristics amid macroeconomic uncertainty. For Australian superannuation funds, the liquidity event provides dry powder for redeployment across alternative asset classes or reinforces the case for maintaining venture capital allocations within long-term portfolio construction.
Brandon Capital's superannuation fund investors—primarily Australian pension funds—stand to benefit materially from the sale proceeds. The deal illustrates the outsized return potential embedded in venture capital allocations within superannuation portfolios, where a single successful biotech exit can deliver multiples on capital deployed across an entire fund vintage.
The Myricx acquisition reflects Novartis's strategic focus on expanding its oncology pipeline through acquisition of development-stage assets. For institutional investors and family offices with exposure to venture capital vehicles or direct biotech holdings, the transaction signals continued pharmaceutical industry appetite for innovative cancer therapies, particularly those in early development phases where acquisition multiples remain elevated relative to mature-stage programs.
The timing of this exit in mid-2026 aligns with a broader institutional reallocation toward life sciences and healthcare innovation, sectors that have demonstrated resilience and defensive characteristics amid macroeconomic uncertainty. For Australian superannuation funds, the liquidity event provides dry powder for redeployment across alternative asset classes or reinforces the case for maintaining venture capital allocations within long-term portfolio construction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.